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Phenobarbital is one of the oldest medications used for the treatment of epilepsy. 
Although its use has declined in many developed nations, phenobarbital is still a first-line 
treatment in several developing countries across the globe. If possible, current American 
Academy of Neurology guidelines advise against the use of phenobarbital during pregnancy 
due to an increased risk for structural malformations. However, less is known about the risk 
that prenatal exposure to phenobarbital poses to the cognitive and behavioral development of 
the child. Adams et al (in progress) have shown that, in comparison to demographically 
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matched controls, children prenatally exposed to phenobarbital for the treatment of maternal 
epilepsy have a significant reduction in general mental ability and verbal intelligence. In this 
paper, we aim to further explore the impact of prenatal exposure to phenobarbital on verbal 
abilities by examining performance on individual verbal subtests within the original testing 
battery. The performance of children that were prenatally-exposed to phenobarbital and 
demographically matched controls was compared on a selection of verbal subtests from the 
Wechsler Intelligence Scale for Children, 3rd Edition (WISC-III ), the Stanford-Binet 
Intelligence Scales, 4th Edition (SB-IV), and the Wechsler Memory Scale, Revised (WMS-
R). Maternal intelligence was assessed with the Wechsler Abbreviated Intelligence Scale, 
Revised (WAIS-R). Initial analyses were conducted to explore the effects of sex and 
treatment on verbal performance. However, no significant effects of sex nor any interaction 
effects were found, so sex was removed from later analyses.  ANCOVA controlling for 
maternal intelligence confirmed a significant reduction in general mental ability and verbal 
intelligence in the sample of children prenatally exposed to phenobarbital. Multivariate 
ANCOVA controlling for maternal intelligence revealed a significant effect of exposure 
group on verbal performance across measures.  Follow-up analyses revealed that children 
prenatally exposed to phenobarbital performed significantly worse than controls on the 
Vocabulary and Arithmetic subtests from the WISC-III and on a test of Story Memory from 
the WMS-R. Combined with previous findings by Adams et al., the results of this study 
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According to the World Health Organization (WHO), there are approximately 50 
million people living with epilepsy worldwide (World Health Organization, 2019). It is 
estimated that 25% of individuals living with epilepsy are women of childbearing age 
(Pennell et al., 2012) and in the United States alone, approximately three to five per 1000 
births are to a woman with epilepsy (Harden et al., 2009). Historically, understanding the 
risks that maternal epilepsy during pregnancy poses to the fetus has been challenging, as it 
has been difficult to disentangle the risks associated with the disorder from the risks caused 
by exposure to antiepileptic medications (Holmes et al., 2001). Some researchers originally 
suggested that structural teratogenic effects seen in infants born to women with epilepsy were 
likely due to inheritance of genetic differences associated with maternal epilepsy (Gaily, 
Granstrom, Hiilesma, & Brady, 1988). However, a growing body of literature began to amass 
that compared the outcome of infants exposed to antiepileptic medications in utero with 
infants of women with well-managed, untreated epilepsy and healthy controls. These studies 
found that, while infants exposed to antiepileptic medications often exhibited physical 
anomalies, infants of women with untreated epilepsy did not differ from controls (Nulman, 
Scolnick, Chitaya, Farkas, & Koren, 1997; Holmes, Rosenberger, Harvey, Khosbin, & Ryan., 
2000; Holmes et al., 2001). In general, these studies, along with others, suggested a link 
between antiepileptic medications and structural abnormalities and established the older 
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antiepileptic medications, including carbamazepine, phenytoin, valproate, and phenobarbital, 
as teratogens (Hill, Verniaud, Horning, McCulley, & Morgan, 1974; Hanson & Smith, 1976; 
Seip, 1976; Jones, Lacro, Johnson, & Adams, 1989; Jones & Chambers, 1992; Nulman et al., 
1997; Holmes et al., 2000; Holmes et al., 2001). In addition, more severe teratogenic effects 
were reported in infants exposed to treatment at higher doses and polytherapy treatment 
regimens (Holmes et al., 2001; Harden et al., 2009).  
For many women with epilepsy, discontinuation of medication during pregnancy is 
not an option due to risks of maternal physical injury, mortality, or effects on infant birth 
weight or prematurity (Battino & Tomson, 2007; Chen, Chiou, Lin, & Lin, 2009). Therefore, 
management of treatment must aim to maintain or decrease seizure frequency while also 
considering the risk that exposure to antiepileptic drugs poses to the fetus. Indeed, in order to 
reduce the risk of congenital malformations and cognitive impairment, the American 
Academy of Neurology (AAN) has recommended monotherapy at the lowest effective dose 
and cautions against the use of polytherapy during pregnancy (Harden et al., 2009). 
First discovered in 1912, phenobarbital is one of the oldest medications that has been 
used to effectively treat epilepsy (López-Muñoz, Ucha-Udabe, & Alamo, 2005). 
Phenobarbital exerts its primary anti-seizure effect through allosteric binding to the GABAA 
receptor, leading to a prolonged influx of chloride and hyperpolarization of the postsynaptic 
membrane (Rogawski & Porter, 1990). Treatment with phenobarbital has been associated 
with adverse side effects in patients, including sedation, changes in mood, and impaired 
cognition (Kwan & Brodie, 2004). When compared to healthy controls, patients with general 
epilepsy who were treated with phenobarbital monotherapy showed adverse cognitive side 
effects, including slowed motor movements, slower processing speed, and impaired attention 
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(Manni et al., 1993). Furthermore, in a double-blind randomized trial in which patients with 
partial and secondary generalized tonic-clonic seizures were assigned to a treatment group, 
almost 50% of patients receiving phenobarbital withdrew from the study due to reported 
toxicity (Mattson et al., 1985). Due to these adverse side effects and poor tolerability by 
some patients, in the United States and many other developed nations, phenobarbital 
prescriptions have decreased in favor of newer antiepileptic medications (Kwan & Brodie, 
2004; Brodie & Kwan, 2012), including during pregnancy (Meador et al., 2018). However, 
due to its low cost and high efficacy, phenobarbital remains a first-line treatment for epilepsy 
in low- and middle-income countries (World Health Organization, 2019).  
During pregnancy, phenobarbital readily crosses the placenta and enters the fetal 
chamber (Melchior, Svensmark, & Trolle, 1967). Because phenobarbital has been associated 
with an increased risk of cardiac and oral cleft malformations (Hernández-Díaz et al., 2012), 
current guidelines for treatment during pregnancy advise against the use of phenobarbital if 
possible (Harden et al., 2009). However, in many nations, phenobarbital remains one of the 
only treatment options (Kwan & Brodie, 2004), and while it has been established to have 
structural teratogenic effects, less is known about how prenatal exposure to phenobarbital 
impacts the cognitive and behavioral development of the offspring.  
Some of the earliest evidence to suggest a neuroteratogenic risk of phenobarbital has 
come from rodent models of gestational and neonatal exposure to the drug. Early research 
established that gestational exposure to phenobarbital from mid-to-late gestation resulted in 
decreased brain weight in exposed pups and reductions in cerebellar Purkinje cells and 
hippocampal pyramidal cells (Yanai, Rosselli-Austin, & Tabakoff, 1979). Gestational 
exposure has also resulted in behavioral alterations at several timepoints in development 
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(Christensen, Gonzalez, & Rayburn, 2004). As pups, exposed mice demonstrated fewer 
vocalizations following maternal separation and a greater startle response to a stimulus. As 
adults, phenobarbital-exposed offspring showed decreased motor activity, increased startle to 
a stimulus, increased anxiety-like behavior, and impaired learning on a tube runway. 
Because the neonatal period from days 1 to 10 in rodents is estimated to align with the third 
trimester in humans (Clancy, Finlay, & Darlington, 2007), models of neonatal exposure to 
phenobarbital have also been used to inform the neuroteratogenic risk of the medication. Similar to 
gestational exposure, treatment with phenobarbital from the first to third week resulted in reduced 
brain weight in pre-weaning (Schain & Watanabe, 1975) and adolescent mice (Yanai & Bergman, 
1981). The total area of the cerebellum and of the dentate gyrus of the hippocampus were also 
reduced in mice treated with phenobarbital, and there was a reduction in cerebellar Purkinje and 
granular cells and hippocampal pyramidal and granule cells (Yanai & Bergman, 1981). Within the 
cerebellum, there were lasting decreases in dendritic spine densities of Purkinje cells (Yanai & Iser, 
1981).  
Noting the reduction in total brain weight and in specific populations of neurons in 
phenobarbital-exposed animals, several groups have attempted to uncover possible 
mechanisms of action, including impaired neurogenesis and increased apoptosis. Following 
in utero phenobarbital exposure from mid- to late-gestation, there was decreased proliferation 
of Purkinje cells, pyramidal cells, and cells of the cortex in young offspring (Yanai, Woolf, 
Feigenbaum, 1982). Decreased proliferation was also seen throughout the brain following 
neonatal treatment with phenobarbital during the first week of life and resulted in decreased 
production of neurons at P15 (Stefovska et al., 2008). By adulthood, phenobarbital treated 
mice showed impaired spatial memory and structural abnormalities in the hippocampus and 
cingulate cortex (Stefovska et al., 2008). Combined, the results of these studies suggest that 
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phenobarbital exposure during gestation and neonatal periods impairs cell proliferation and 
neurogenesis and that these early alterations result in structural and functional brain 
abnormalities that persist into later life.  
In addition to impairing the birth of new cells, research has also suggested that 
neonatal treatment with phenobarbital induces widespread apoptosis throughout the 
developing brain. Treatment with phenobarbital throughout the first month of life resulted in 
increased apoptosis throughout the brain, including in the hippocampus, thalamic nuclei, 
subiculum, amygdala, hypothalamus, caudate nucleus, nucleus accumbens, and globus 
pallidus (Bittigau, Sifringer, & Ikonomidou, 2003). Acute treatment with phenobarbital in 
pups also induced apoptosis in the striatum, ventral thalamus, and lateral thalamus, and these 
results were amplified by polytherapy treatment combined with lamotrigine (Katz, Kim, 
Gale, & Kondratyev, 2007).  
Combined, studies conducted in rodent models suggest that phenobarbital exposure 
during periods of early brain development disrupts key developmental processes, including 
neurogenesis and apoptosis, and results in widespread structural changes in the brain. In 
addition to the previously described behaviors, rodents exposed to phenobarbital during the 
gestational or neonatal periods have also shown behavioral alterations in adulthood, 
including deficits in spatial learning and memory (Yanai, 1989; Forcelli et al., 2012; 
Stefovska et al., 2008), impaired learning in a passive avoidance paradigm (Frankel et al., 
2016; Gutherz et al., 2014), decreased motor activity and coordination (Christensen et al., 
2004; Forcelli et al, 2012), impaired cued fear conditioning (Forcelli et al., 2012), increased 
or decreased anxiety-like behavior (Christensen et al., 2004, Forcelli et al., 2012, Frankel et 
al, 2016), and impaired prepulse inhibition (Forcelli et al., 2012; Gutherz et al, 2014). Given 
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the structural changes that are seen in early development, several researchers have 
hypothesized the link between early brain development and the behavioral changes seen at 
later ages. Several behaviors, including spatial learning and memory and passive avoidance 
have been attributed to early changes in hippocampal structure (Stevofska et al., 2008; 
Frankel et al., 2016). Furthermore, Gutherz et al. (2014) hypothesized that deficits in passive 
avoidance could also be linked to early apoptosis in the frontal cortex, leading to 
impairments in executive functioning. Forcelli et al. (2012) considered early apoptosis in the 
amygdala, striatum, and nucleus accumbens as a possible explanatory factor for impaired 
prepulse inhibition in phenobarbital-exposed animals.  
Overall, as illustrated above, although it is unclear how specific effects seen in 
rodents are related to clinical outcomes in humans exposed to phenobarbital in utero, studies 
in rodents raise concern about the possible lifelong neuroteratogenic effects of phenobarbital 
exposure in early development. Despite this fact, however, less is known about cognitive and 
behavioral outcomes in infants and children prenatally exposed to phenobarbital.  
To date, several cohorts in North America and Europe have been established to study 
how prenatal exposure to monotherapy with antiepileptic medications impacts the 
neuropsychological functioning of the child at various ages in development, and these 
cohorts have been pivotal in classifying the neuroteratogenic risk of antiepileptic 
medications, such as phenytoin, carbamazepine, and valproic acid (Bromley & Baker, 2017). 
Unfortunately, however, due to its frequent use in polytherapy regimens and to its declining 
use in developed nations, phenobarbital has not been included as a primary medication of 
interest in these studies (Lutes, Borchelt, Janulewicz, & Adams, 2018). Of the limited studies 
that do exist for phenobarbital, the majority suggest that prenatal exposure to phenobarbital is 
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not associated with adverse effects on neuropsychological functioning in toddlers (Thomas et 
al., 2008) or children (Dean et al, 2002; Thomas, Sukumaran, Lukose, Geourge, & Sarma, 
2007). One study, however, found poor performance in spelling and arithmetic for children 
prenatally exposed to phenobarbital (van der Pol, Hadders-Algra, Huisjes, & Touwen, 1991), 
and lowered verbal performance has been reported in adult men exposed to phenobarbital 
during the prenatal period (Reinisch, Sanders, Mortensen, & Rubin, 1995). The 
methodological rigor of these studies is questioned, however, by sample sizes less than 20 
per exposure group (van der Pol et al., 1991; Dean et al., 2002; Thomas et al., 2007; Thomas 
et al., 2008), lack of a comparison to a control group (Thomas et al., 2008), and failure to 
adjust for possible confounding variables, such as maternal education and measures of 
maternal mental ability (IQ scores) (van der Pol et al., 1991, Reinisch et al., 1995; Dean et 
al., 2002; Thomas et al., 2007; Thomas et al., 2008).  
Understanding the need for more research in this area, Adams et al. (manuscript in 
progress) assessed the cognitive performance of 34 phenobarbital-exposed children and 34 
unexposed control children that were matched for maternal age at delivery, maternal 
socioeconomic status (including education), gender, and age at testing. Research on 
phenytoin-exposed and carbamazepine-exposed children and their unexposed matches was 
conducted in parallel and is not reported herein. Following adjustment for matching, siblings, 
and maternal IQ, in comparison to their matched controls, children in the phenobarbital-
exposed group exhibited a significant reduction in verbal IQ (VIQ) and full-scale IQ (FSIQ). 
Because performance IQ (PIQ) did not differ significantly due to phenobarbital exposure, 
reductions in full-scale IQ were interpreted as largely resulting from impaired performance in 
verbal areas.   
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In order to further explore the profile of cognitive strengths and weaknesses in 
children prenatally exposed to phenobarbital, the current paper examines performance on 
individual verbal subtests in the neuropsychological battery for a subset of subjects from 












































Recruitment of Subjects 
 
Recruitment of subjects was conducted in two phases. During Phase I (1983-1993), 
the primary source of recruitment, women were recruited from a surveillance study being 
conducted at five maternity hospitals in the Boston area (Holmes, Harvey, Brown, Hayes, & 
Khoshbin, 1994; Holmes et al., 2001). During Phase II (1996-2000), additional subjects were 
recruited through referrals from neurologists, pediatricians, and obstetricians/gynecologists 
as well as through medical record evaluations by a large health maintenance organization in 
the Boston area. Flyers, newspaper and radio advertisements, and referrals from other 
subjects in the study were also used to recruit subjects from the community.  
Selection of Subjects 
 
Selection for participation in the study was dependent upon inclusion criteria, 
exclusion criteria, and the ability to match between groups. Women were excluded from 
participation in the study if they experienced one or more tonic-clonic seizures during 
pregnancy, had exposure to polytherapy during pregnancy, or if they were exposed to a 
known teratogen. Seizure and treatment histories were determined through medical record 
review by a neurologist and exposure to a teratogen was assessed by a teratologist at 
Massachusetts General Hospital. For inclusion in the study, both parents of the child had to 
demonstrate normal intelligence on the Raven’s Progressive Matrices Test. If qualified for
 10 
 
 participation in the study, maternal intelligence was also assessed using the Weschler 
Abbreviated Intelligence Scale (WAIS). 
Participants were excluded from the study if the child was not a singleton birth, if the 
child had a postnatal history of illness or injury that could impact neuropsychological 
functioning, if the child had a visual or auditory impairment, or if English was not the child’s 
first language. Evaluation of the presence of any of these criteria in children was assessed 
through a review of medical records, a parental questionnaire, and auditory and visual 
screening tasks.  
If a subject met participation criteria, matching was then conducted in order to 
balance the maternal and child demographics of exposed and unexposed participants. 
Children from the phenobarbital exposure group were matched with an unexposed control 
child. Matching criteria included maternal age at child’s birth, maternal socioeconomic status 
(including education), child age at testing, and child sex.  
Neuropsychological Assessments 
 
Children in the original study were administered a comprehensive neuropsychological 
screening battery that included the Wechsler Intelligence Scale for Children, Third Edition 
(WISC-III) and select subtests from the Stanford-Binet Intelligence Scale, Fourth Edition 
(SB-IV) and the Wechsler Memory Scale-Revised (WMS-R). All assessments were 
conducted by a trained psychometrist that was blind to exposure group.  
The WISC-III is a standardized assessment that provides composite scores of verbal 
intelligence (VIQ), performance intelligence (PIQ) and full-scale intelligence (FSIQ). Verbal 
subtests that were administered include Information (a test of general factual knowledge), 
Arithmetic (a test of mental computation given verbal instructions), Vocabulary (a test of 
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word knowledge), and Digit Span (a test of verbal short-term memory). Composite scores 
have a mean of 100 and standard deviation of 15. Subtests have a mean score of 10 and a 
standard deviation of 3.  Both the VIQ and FSIQ were scored according to prorating criteria 
described in the WISC-III manual (Wechsler, 1991).  
The SB-IV is a standardized intelligence assessment comprised of 15 subtests that 
provide an assessment of cognitive ability in verbal and non-verbal areas. In this study, 
children were administered the Sentence Memory subtest as a measure of verbal memory. 
This subtest has a mean scaled score of 50 and a standard deviation of 8 (Thorndike, Hagen, 
& Sattler, 1986). 
The WMS-R is a standardized memory assessment comprised of thirteen subtests 
from which five index scores can be derived (Wechsler, 1987). To assess verbal memory 
abilities, children were administered a task of immediate-recall story memory. 
In addition to the assessment of children’s mental abilities, maternal intelligence was 
assessed using the Wechsler Abbreviated Intelligence Scale-Revised (WAIS-R). The WAIS-
R provides an assessment of VIQ, PIQ, and FSIQ. Composite scores have a mean of 100 and 
standard deviation of 15 (Wechsler, 1981). 
Statistical Analyses 
 
To account for possible variance attributed by sibling relationships within the sample, 
every effort was made to utilize one child per family and for the first-born child to be the one 
included in analyses. There were two exceptions made, however, in order to provide 
demographic, age, and gender matching and to protect sample size. In the unexposed control 
group, there were two sets of siblings (4 subjects) that were matched to phenobarbital-
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exposed subjects. To balance the possible impact of sibling-based variance in the exposed 
group, two sets of phenobarbital-exposed siblings were also retained.  
The effectiveness of our matching was assessed by using two-tailed independent 
samples t-tests to examine demographic characteristics of the exposed and unexposed groups. 
Because this paper addresses a subset of phenobarbital-exposed children that were included 
in the work by Adams et al., we were interested in confirming that our sample showed a 
similar pattern of performance on the WISC-III as seen in the full sample (Adams et al., in 
progress). Therefore, performance on the FSIQ, VIQ, and PIQ were examined using 
univariate analysis of covariance in which exposure group and sex were included as factors 
and maternal FSIQ was included as a covariate. 
The effects of prenatal exposure to phenobarbital on verbal abilities were assessed 
using multivariate analysis of covariance (ANCOVA), in which exposure group and sex were 
included as factors and maternal FSIQ was included as a covariate. For this analysis, scores 
on all verbal subtests in the battery were included as dependent variables. These subtests 
included Information, Arithmetic, Vocabulary, and Digit Span from the WISC-III, Sentence 
Memory from the SB-IV, and Immediate Recall Story Memory from the WMS-R. Upon 
finding a significant multivariate effect, univariate ANCOVAs controlling for maternal FSIQ 
were conducted to determine which specific dependent variables contributed to the 
significant multivariate effect. 
All analyses were conducted using IBM SPSS Statistics 27 for Macintosh, and all figures 







Approval for Work with Human Subjects 
 
This study was approved by the Massachusetts General Hospital’s Human Studies 
Committee and the University of Massachusetts Institutional Review Board. All parents 
provided written informed consent, and if a child was fourteen years of age or older, they 
were also asked to provide written assent prior to participating in their evaluation. No 










































As shown in Table 1, the study population consisted of 26 phenobarbital (PB)-
exposed subjects and 26 unexposed controls. Demographic variables, such as age at testing, 
maternal age at birth, and maternal education did not differ statistically between the two 
groups (Age at Testing: t(50) = -0.030, p = 0.976), Maternal Age: t(48) = 0.676, p  = 0.502), 
Maternal Education: t(49) = 0.161, p = 0.873). Likewise, maternal FSIQ was similar between 
the two groups (t(49) = -0.893, p = 0.376).  
Unadjusted means and standard deviations for performance on the 
neuropsychological measures are presented in Table 2. In general, for both exposure groups, 
mean scores on all measures were consistent with performance in the average range or 
higher. A determination of the number of children performing two standard deviations or 
more below the mean revealed one subject from the PB-exposed group and no subjects from 
the control group.  
In initial confirmatory analyses, univariate ANCOVAs controlling for maternal FSIQ 
were conducted to examine the effects of phenobarbital exposure and sex on individual 
composite scores of the WISC-III. There was a significant effect of Exposure Group on FSIQ 
(F(1,46) = 4.467, p = 0.040, η2p = 0.089) and VIQ (F(1,46) = 5.889, p = 0.019, η2p = 0.113), 
but no effect on PIQ (F(1,46) = 2.009, p = 0.163, η2p = 0.042). There were no significant 
effects of Sex (FSIQ: F(1, 46) = 1.598, p = 0.213, η2p = 0.034; VIQ: F(1,46) = 0.502,
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p = 0.482, η2p = 0.011; PIQ: F(1,46) = 3.174, p = 0.081, η2p = 0.065) and no Exposure 
Group by Sex interaction (FSIQ: F(1,46) = 0.072, p = 0.790, η2p = 0.002; VIQ: F(1,46) = 
1.188, p = 0.281, η2p = 0.025 ; PIQ: F(1,46) = 0.615, p = 0.437, η2p = 0.013.  Therefore, 
further analyses were conducted with Sex removed from the model. As shown in Table 3 and 
Figure 1, ANCOVA controlling for maternal FSIQ revealed a significant effect of 
phenobarbital exposure on FSIQ (F(1,48) = 4.967, p = 0.031, η2p = 0.094) and VIQ (F(1,48) 
= 7.255, p = 0.010, η2p = 0.131), while PIQ (F(1,48) = 1.688, p = 0.200, η2p = 0.034) did 
not significantly differ between the two groups.  
After confirming decreased verbal performance on the WISC-III in our sample of PB-
exposed subjects, our primary interests were in determining if there was a difference across 
verbal measures in our neuropsychological battery, and if so, which specific areas of verbal 
cognition differed between groups. In initial analyses, multivariate ANCOVA controlling for 
maternal FSIQ was conducted to examine the effects of phenobarbital exposure and sex on 
the aggregate group of verbal subtests. As shown in Table 4, the analysis revealed a 
significant effect of Exposure Group (F(6,39) = 2.584, Wilks’ Λ = 0.716, p = 0.033, η2p = 
0.284). There was no significant effect of Sex (F(6,39) = 0.847, Wilks’ Λ = 0.885, p = 0.542, 
η2p = 0.115) and no Exposure Group by Sex Interaction (F(6,39) = 1.01, Wilks’ Λ = 0.865, p 
= 0.433, η2p = 0.135), so analyses were conducted with Sex removed from the model. The 
adjusted means by Sex and Exposure Group are shown in Appendix A. 
Multivariate ANCOVA controlling for maternal FSIQ revealed a significant effect of 
exposure group on verbal measures (F(6, 41) = 2.647, Wilks’ Λ = 0.721, p = 0.029, η2p = 
0.279). As shown in Table 5 and Figure 2, follow-up univariate between-group analyses 
revealed no individually-significant differences in the scores of the PB-exposed and control 
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children on Information (F(1,46) = 2.522, p = 0.119, η2p = 0.052), Digit Span (F(1,46) = 
1.233, p = 0.273, η2p = 0.026), or Sentence Memory (F(1,46) = 1.744, p = 0.193, η2p = 
0.037). However, PB-exposed children performed significantly worse than controls on 
Vocabulary (F(1,46) = 4.743, p = 0.035, η2p = 0.093), Arithmetic (F(1,46) = 11.502, p = 











































In a previous study, Adams et al. (in progress) found that children of women with 
epilepsy that were prenatally exposed to phenobarbital monotherapy demonstrated 
significantly lower verbal intelligence and full-scale intelligence on the WISC-III than 
unexposed children born to women without epilepsy and matched for demographic variables. 
Here, we have examined the effects of phenobarbital on specific verbal abilities assessed by a 
group of verbal subtests selected from the WISC-III, the SB-IV, and WMS-R. We have 
shown that, when compared to demographically matched, unexposed children, phenobarbital-
exposed children performed significantly worse on a group of verbal subtests.  Univariate 
examination of performance on specific measures revealed significant effects on performance 
on a test of word knowledge (Vocabulary), a test of mental arithmetic (Arithmetic), and a test 
of verbal memory (IR-Story Memory). 
Although the research investigating the effects of prenatal exposure to phenobarbital 
on neurodevelopment is limited, our findings are consistent with current reported research.  
Reinisch et al. (1995) retrospectively ascertained 33 adult men who had been exposed to 
phenobarbital monotherapy in utero for reasons other than epilepsy (e.g. hypertension, 
preeclampsia, eclampsia, sedation). When evaluated on the Wechsler Abbreviated 
Intelligence Scale (WAIS), phenobarbital-exposed men demonstrated significantly lower 
than predicted verbal intelligence. Although other antiepileptic medications, such as
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phenytoin, carbamazepine, valproic acid, and lamotrigine, exert their antiepileptic effects 
through different initial mechanisms than phenobarbital, several researchers have also 
reported a weakness in verbal abilities during at least one developmental timepoint in 
prenatally exposed children (Meador et al., 2011, 2012; Nadebaum et al., 2001; Baker et al., 
2015). These common findings among different antiepileptic medications merit further 
investigation to better understand possible common mechanisms, final common pathways, or 
vulnerabilities.   
The primary finding in this study was that, in comparison to controls, children 
prenatally exposed to phenobarbital showed a significant overall weakness on measures of 
verbal performance, with specific weaknesses on a test of mental arithmetic, story recall, and 
vocabulary. Van der Pol et al. (1991) conducted neurodevelopmental follow-up on 12 
prospectively ascertained children that had been prenatally exposed to phenobarbital 
monotherapy for maternal epilepsy. When compared to demographically matched control 
children, the phenobarbital-exposed group had significantly more children that performed 
poorly on standardized tests of spelling and arithmetic, though the specific measures were not 
described. Phenobarbital-exposed children in our study also demonstrated lower performance 
on a test of vocabulary knowledge and had an impaired ability to immediately recall stories 
that they had heard. To our knowledge, this is the first report of impaired performance on 
these subtests in phenobarbital-exposed children.  
It is unclear why children performed worse on Vocabulary, Arithmetic, and Story 
Memory, while other verbal subtests, such as Information, Digit Span, and Sentence Memory 
were not significantly impacted. Nicholson and Alcorn (1993) have discussed cognitive 
abilities that influence high or low performance on subtests of the WISC-III. According to 
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their assessment, performance on the Arithmetic subtest of the WISC-III relies on verbal 
output ability, focused attention, ability to perform simple math, short-term memory, low 
distractibility, and a good educational background. In their assessment, performance on the 
Vocabulary subtest is also dependent on verbal output abilities and a good educational 
background, but also requires an understanding of culture. Ernst, Warner, Morgan, Townes, 
Eiler, and Coppel (1986) conducted a factor analysis of the Weschler Memory Scale and 
found that focused attention and concentration abilities appear to be important factors in 
determining performance on the story memory component of the assessment. Because 
phenobarbital exposed subjects in this study performed similarly to controls on three 
subtests, it is unlikely that generalized verbal output abilities are the primary contributor to 
the differences in performance between groups. Due to the importance of attention and low 
distractibility for performance on the Arithmetic and Story Memory subtests, however, it is 
possible that the verbal working memory and attentional abilities required for these subtests 
challenged the abilities of children prenatally exposed to phenobarbital. To further 
understand the specific profile of cognitive strengths and weaknesses in phenobarbital-
exposed children, future studies should include a neuropsychological battery that also 
contains robust measures of working memory abilities, attention, and distractibility.  
Although verbal abilities in humans are unable to be directly studied in rodent 
models, the neuroteratogenic risk of phenobarbital can also be informed by animal models of 
gestational and neonatal exposure to the drug. Few studies have examined behavioral 
outcomes in pups or adolescent rodents, but behavioral alternations have been observed in 
adult rodents exposed to phenobarbital during periods of early brain development. Of interest 
to our study, Gutherz et al. (2014) reported that adult rats who were treated with 
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phenobarbital in the neonatal period exhibited poor performance on a task of passive 
avoidance. Although passive avoidance has been reported to be a hippocampal-dependent 
behavior (Frankel et al., 2016), Gutherz et al. (2014) also hypothesized that deficits in 
passive avoidance could be linked to early apoptosis in the frontal cortex, leading to deficits 
in executive functioning in phenobarbital-exposed animals. Significant apoptosis in the 
frontal cortex of P7 pups has been reported following acute exposure to phenobarbital in the 
neonatal period (Bittigau, Sifringer, & Iknonomidou, 2003). Additionally, Bittigau, Sifringer, 
& Ikonomidou (2003) also reported significant apoptosis following phenobarbital exposure 
in two brain regions reported to be part of the brain network for verbal working memory in a 
pediatric population (Yang et al., 2015), including the frontal cortex and cingulate cortex. 
Currently, a direct link between research in animals and behavioral outcome in humans has 
not been established, but more focused studies in animals at different developmental time 
points will be pivotal to informing the risk that early phenobarbital exposure poses to the 
development of the brain and behavior. 
Although the animal literature suggests a neuroteratogenic risk of phenobarbital, 
currently, it is unclear exactly how research in animal models relates to neuropsychological 
outcomes in children that are exposed to phenobarbital in utero. However, Meador & Loring 
(2016) have suggested a correlation between outcomes of apoptotic models of exposure to 
antiepileptic medications and cognitive outcome in children. In an animal model of neonatal 
phenobarbital-induced apoptosis, widespread programmed cell death was seen at plasma 
concentrations of 25-35 μg/mL, a level stated to be of therapeutic relevance in human infants 
administered phenobarbital (Bittigau, Sifringer, & Ikonomidou, 2003). In a small sample of 
newborns exposed to phenobarbital in utero, average peak plasma concentration was 16.1 
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μg/mL, but levels as high as 21.6 μg/mL were reported in some infants (Zuppa et al., 2011). 
Although the mean phenobarbital concentration in prenatally exposed infants is thought to be 
less than the concentration seen in Bittigau, Sifringer, & Iknomidou (2003), it is unknown if 
lower concentrations of phenobarbital may result in apoptosis in light of potentially increased 
vulnerability of the developing brain at earlier stages. However, due to the possible 
association between drug-related apoptosis in animals and cognitive outcome in humans, 
Meador & Loring (2016) have suggested that the United States Food and Drug 
Administration require preclinical testing with apoptotic models to inform the 
neuroteratogenic risk of new antiepileptic medications prior to their use in humans.  
The results of our study add to the limited amount of literature exploring the 
cognition of children prenatally exposed to phenobarbital. Specifically, our results suggest 
decreased performance on a test of vocabulary, decreased mental arithmetic abilities, and 
impaired verbal memory for stories in comparison to control children. Our study was limited 
by small sample size, lack of confidence in the consistency of classifications of types of 
maternal epilepsy, and incomplete information on doses of phenobarbital used throughout 
pregnancy. In order to truly understand the full risk posed by prenatal exposure to 
phenobarbital, future studies should examine dose-response relationships and risk of 
teratogenicity by length of exposure, when possible. Despite these limitations, however, 
strengths of our study include careful matching of exposed and control subjects on important  
demographic variables; exclusion of pregnant women who had seizures during pregnancy, 
polytherapy with other anticonvulsant medications, or exposures to other known teratogens;  
use of standardized neuropsychological assessments conducted by examiners that were 
blinded to exposure group: and statistical adjustment for maternal intelligence.  
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Although phenobarbital use has declined in developed, industrial nations, for many 
parts of the developing world there is a choice between treatment with phenobarbital or no 
treatment at all (Kwan & Brodie, 2004). Combined with the results of Adams et al. (in 
progress), this research suggests an effect of prenatal exposure to phenobarbital on verbal 
abilities, specifically vocabulary knowledge, mental arithmetic, and immediate recall verbal 
memory, that is consistent with previously published literature. Combined with animal 
literature that provides mechanistic insight into morphological and functional changes that 
occur in response to early phenobarbital exposure, these studies suggest that use of 
phenobarbital during pregnancy poses a neuroteratogenic risk to the developing infant. 
Future studies should aim to further explore neurodevelopmental outcomes in larger samples 
of children prenatally exposed to phenobarbital monotherapy. Specific areas of research 
could include exploring dose-response relationships, exposure durations, and outcomes 
related to cognitive abilities, such as memory and attention. Furthermore, research should be 
conducted to explore alternative efficacious and low-cost treatments for use in pregnant 



















Table 1 Demographic Characteristics of Study Population by Exposure Groupa 
Children Control (n = 26) 
PB-Exposed 
(n = 26) 
Age at Testing, Years 9.8 (2.7) 9.7 (2.7) 
Age Range, Years 6.0-15.8 6.6-16.3 
Sex (M:F) 11:15 11:15 
Mothers   
Age at Child’s Birth, Years 32.5 (4.9) 33.3 (4.2) 
Education, Years 15.9 (2.4) 16.0 (2.8) 
Full Scale IQb 114.3 (12.8) 110.8 (15.1) 
a Values are presented as mean (standard deviation) 














Table 2 Unadjusted Scoresa on Neuropsychological Measures 
aValues are presented as mean (standard deviation) 





























WISC-III Control (n = 26) 
PB-Exposed 
(n = 26) 
Full Scale IQ 113.12 (11.17) 102.88 (16.62) 
Verbal IQ 115.19 (9.80) 103.88 (16.68) 
Performance IQ 108.88 (13.27) 101.62 (16.13) 
Information 12.96 (3.07) 11.31 (3.70) 
Vocabulary 13.12 (2.92) 11.08 (3.53) 
Arithmetic 12.31 (2.92) 9.12 (3.16) 
Digit Span 11.23 (2.34) 10.46 (2.79) 
WMS-Rb   
Immediate Recall Story Memory 10.58 (3.45) 8.67 (3.41) 
SB-IVb   
Sentence Memory* 54.17 (6.78) 52.13 (8.29) 
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Table 3 Adjusted Means for Composite Scores of the WISC-III Following Univariate 










Full Scale IQ 111.88 (106.53 - 117.24) 
103.54 
(98.29 - 108.79) 
4.967 
(0.031) 
Verbal IQ 114.46 (109.14 - 119.78) 
104.44 
(99.23 - 109.66) 
7.255 
(0.010) 
Performance IQ 107.28 (101.76 - 112.81) 
102.27 




































Figure 1 Mean Composite Scores on the WISC-III by Exposure Group. Vertical bars 
represent the 95% CI. Data were analyzed with univariate ANCOVA and adjusted for 














































































Table 4 Adjusted Means for Performance on Neuropsychological Measures Following 
Multivariate ANCOVA to Examine the Effects of Exposure Group and Sex on Verbal 










Information 12.59 (11.25 – 13.94) 
11.25 
(9.89 – 12.61) 
1.994 
(0.165) 
Vocabulary 12.88 (11.58 – 14.19) 
10.92 
(9.59 – 12.24) 
4.493 
(0.40) 
Arithmetic 12.07 (10.79 – 13.36) 
9.21 
(7.90 – 10.52) 
9.805 
(0.003) 
Digit Span 11.13 (10.09 - 12.17) 
10.51 
(9.45 - 11.56) 
0.720 
(0.401) 
Sentence Memory 54.45 (51.50 – 57.40) 
52.19 
(49.19 – 55.18) 
1.170 
(0.285) 
Immediate Recall Story 
Memory 
10.92 
(9.54 - 12.31) 
8.69 


































Table 5 Adjusted Means for Performance on Neuropsychological Measures Following 
Multivariate ANCOVA to Examine Effects of Exposure Group on Verbal Abilities. Means 










Information 12.72 (11.42 - 14.02) 
11.25 
(9.93 - 12.58) 
2.522 
(0.119) 
Vocabulary 12.96 (11.70 - 14.23) 
11.00 
(9.71 - 12.29) 
4.743 
(0.035) 
Arithmetic 12.14 (10.90 - 13.39) 
9.14 
(7.88 - 10.41) 
11.502 
(0.001) 
Digit Span 11.29 (10.27 - 12.32) 
10.49 
(9.44 - 11.53) 
1.233 
(0.273) 
Sentence Memory 55.11 (52.12 - 58.11) 
52.30 
(49.24 - 55.35) 
1.744 
0.193 
Immediate Recall Story 
Memory 
10.76 
(9.41 - 12.11) 
8.75 










Figure 2 Mean Performance on Verbal Subtests of the Neuropsychological Battery by 
Exposure Group. Vertical bars represent the 95% CI. Data were analyzed with univariate 






















































































APPENDIX A. ADJUSTED MEANS FOR PERFORMANCE ON VERBAL MEASURES 
BY SEX AND EXPOSURE GROUP FOLLOWING MULTIVARIATE ANCOVA.  
Means are adjusted for maternal FSIQ. Phenobarbital-exposed children performed 
significantly worse on verbal measures than control children (p < 0.05).  There was no effect 












Females 13.22 (11.52 - 14.91) 
11.26 
(9.51 - 13.01) -- 
Males 11.97 (9.90 - 14.05) 
11. 237 
(9.16 - 13.3) -- 
Total 12.59 (11.25 - 13.94) 
11.25 




Females 13.29 (11.64 - 14.94) 
11.40 
(9.70 - 13.11) -- 
Males 12.48 (10.46 - 14.50) 
10.43 
(8.40 - 12.46) -- 
Total 12.88 (11.58 - 14.19) 
10.92 




Females 12.41 (10.78 -14.04) 
8.81 
(7.13 - 10.49) -- 
Males 11.74 (9.75 - 13.73) 
9.62 
(7.62 - 11.61) -- 
Total 12.07 (10.79 - 13.36) 
9.21 




Females 11.94 (10.62 - 13.25) 
10.38 
(9.03 - 11.74) -- 
Males 10.33 (8.72 – 11.94) 
10.63 
(9.02 - 12.24) -- 
Total 11.13 (10.09 - 12.17) 
10.51 




Females 57.77 (54.05 - 61.50) 
52.85 
(49.00 - 56.70) -- 
Males 51.13 (46.56 - 55.69) 
51.52 
(46.94 - 56.10) -- 
Total 54.45 (51.50 - 57.40) 
52.19 
(49.19 - 55.18) 
1.170 
(0.285) 
Immediate Recall Story 
Memory 
Females 10.13 (8.38 - 11.88) 
9.03 
(7.22 - 10.84) -- 
Males 11.72 (9.58 - 13.86) 
8.35 
(6.20 - 10.50) -- 
Total 10.92 (9.54 - 12.31) 
8.69 
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